BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Update

BrainsWay Ltd. (NASDAQ:BWAY) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 125,100 shares, a growth of 126.2% from the February 28th total of 55,300 shares. Currently, 0.8% of the company’s shares are short sold. Based on an average daily volume of 65,800 shares, the short-interest ratio is presently 1.9 days.

BrainsWay Stock Performance

Shares of NASDAQ:BWAY opened at $9.61 on Friday. BrainsWay has a 52 week low of $4.61 and a 52 week high of $11.79. The company has a market cap of $180.93 million, a PE ratio of 96.11 and a beta of 1.29. The firm has a 50 day simple moving average of $10.29 and a 200 day simple moving average of $9.74.

Institutional Trading of BrainsWay

A number of hedge funds have recently modified their holdings of BWAY. Lazard Asset Management LLC acquired a new position in BrainsWay during the fourth quarter valued at $44,000. JPMorgan Chase & Co. grew its stake in BrainsWay by 316.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock valued at $136,000 after acquiring an additional 11,221 shares in the last quarter. Sei Investments Co. acquired a new position in shares of BrainsWay in the 4th quarter valued at about $149,000. Cubist Systematic Strategies LLC lifted its position in shares of BrainsWay by 14.6% in the fourth quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock worth $181,000 after purchasing an additional 2,446 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of BrainsWay by 10.8% during the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock worth $207,000 after purchasing an additional 2,144 shares during the period. Hedge funds and other institutional investors own 30.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of BrainsWay in a research report on Wednesday, March 12th.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.